New Antibiotics Show Promise in Disrupting Tuberculosis Bacteria
Researchers have identified how a class of experimental antibiotics disrupts the bacterium that causes tuberculosis (TB), offering a potential pathway to urgently needed new treatments. TB remains a significant global health crisis, responsible for approximately 1.2 million deaths annually and ranking among the world’s deadliest infectious diseases. The emergence of drug-resistant strains, particularly in the Asia-Pacific region, underscores the critical need for innovative therapeutic strategies.
How the Antibiotics Work
A study published in Nature Communications investigated the effects of three naturally occurring antibiotic compounds – ecumicin, ilamycin, and cyclomarin – on Mycobacterium tuberculosis, the bacterium responsible for TB. These compounds target the ClpC1–ClpP1P2 complex, a vital protein degradation machine within the bacterium.
The ClpC1–ClpP1P2 complex is essential for breaking down damaged or unnecessary proteins, allowing the bacterium to survive stress and maintain its functions. Without this complex, the TB bacterium cannot survive, making it an attractive target for drug development.
According to Professor Warwick Britton, Laboratory Head in the Centenary Institute’s Centre for Infection & Immunity, the study revealed a surprising level of complexity in how these antibiotic compounds interact with the bacterial system. “TB bacteria depend on this recycling system to stay alive, particularly under stressful conditions inside the human body,” Professor Britton said.
The research showed that the compounds don’t simply shut down the system; instead, each interferes with it in a unique way, causing imbalances throughout the bacterium. This disruption weakens the bacterium’s ability to function, and survive.
A Comprehensive Protein Network Analysis
First author Isabel Barter, a PhD candidate at the University of Sydney who similarly conducted research at the Centenary Institute, explained that the team measured changes across over 3,000 proteins in Mycobacterium tuberculosis. “By tracking changes across most of the bacterium’s protein network, we were able to notice how disrupting a single essential complex can reshape the bacterium’s entire internal protein landscape,” she said.
This detailed understanding provides valuable insights into refining these compounds and designing more effective anti-TB treatments.
Targeting a Promising Drug Target
Professor Richard Payne from the University of Sydney highlighted the potential of directly targeting the ClpC1–ClpP1P2 complex. “Our study highlights the potential of directly targeting this protein degradation system,” Professor Payne said. “By understanding how different compounds interact with it and disrupt its normal function, we can more strategically design the next-generation of anti-TB drugs.”
Expanding Treatment Options
The researchers believe this study represents a significant step toward expanding the pipeline of potential new treatment options for TB, including drug-resistant forms. Further research is needed to translate these findings into clinical applications, but the initial results are promising in the fight against this global health threat.
Ongoing research at the Centenary Institute also focuses on developing new TB vaccines and identifying biomarkers for early detection of the disease. A new mRNA vaccine, developed in collaboration with the University of Sydney and Monash University, has shown effectiveness in pre-clinical trials, boosting immunity against TB. This vaccine, successful in triggering an immune response in mice, also showed improved long-term protection when used as a booster after the traditional BCG vaccine.